在乳腺癌的芳香酶抑制剂治疗期间,绝经后妇女的作用功能
Halia Melnyk1,2, Victoria Vaughan Dickson3, Catherine Bender4
1New York University Rory Meyers College of Nursing, New York, NY, USA. melnyh01@nyu.edu.
Journal of cancer survivorship : research and practice
|October 19, 2024
概括
芳酶抑制剂 (AI) 治疗可以限制乳腺癌幸存者的角色功能. 症状显著影响情绪角色功能,而社会人口统计学和健康因素也会影响治疗期间的身体角色功能.
科学领域:
- 在瘤学瘤学.
- 癌症生存率研究 癌症生存率研究
- 医疗保健服务研究 医疗服务研究
背景情况:
- 芳酶抑制剂 (AI) 治疗是早期激素受体阳性乳腺癌的标准治疗方法.
- 有限的研究存在于人工智能治疗对工作年龄乳腺癌幸存者的角色功能的影响.
- 了解影响角色功能的因素对于在治疗期间和治疗后支持幸存者至关重要.
研究的目的:
- 研究AI治疗18个月期间,治疗前的特征和患者报告的症状如何影响角色的身体 (RP) 和角色的情绪 (RE) 功能.
- 为了比较不同AI治疗方案 (化疗之后的阿纳斯特罗与仅用阿纳斯特罗) 对角色功能的影响.
主要方法:
- 对351名绝经后妇女的纵向数据进行了二次分析,分为三个队列:化疗后使用阿纳斯特罗 (CFAI),仅使用阿纳斯特罗 (AI) 和非癌症对照.
- 线性混合效应建模被用来分析角色的身体和角色的情感功能,使用医学结果研究简单表格36 v2.2.
- 癌症生存率和工作模型指导变量选择和解释.
主要成果:
- 与对照组相比,两组人工智能治疗组在RP功能方面都经历了更大的限制.
- 与只有AI的组相比,CFAI组对RP功能的影响是AI组的两倍.
- 虽然社会人口统计学,健康和症状特征预测了RP限制,但只有症状显著预测了RE限制.
结论:
- 从急性生存到延长生存的过渡存在由于多种因素而导致角色功能减弱的风险.
- 建议在全身治疗期间针对角色功能限制的早期干预措施,以改善工作结果和长期生存质量.
相关概念视频
01:28Menopause
143
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
143
01:22Hormonal Regulation of the Menstrual Cycle
308
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
308
01:30Hormonal Control of the Ovarian Cycle
424
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
424
01:40Bone Remodeling
38.2K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.2K
01:40Hormonal Regulation
43.2K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
43.2K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K